Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease
2008-001965-27Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2008
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Primary endpoint: Primary safety endpoint. Started Jul 2008; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2008-001965-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001965-27.